Anticoagulants

Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and...


In addition to Warfarin ( Coumadin ), there are four non-vitamin K antagonist oral anticoagulants ( NOACs ) available for...


History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation. Researchers have analyzed outcomes in relation to history of...


Historically, Warfarin ( Coumadin ) or Acetylsalicylic acid ( Aspirin ) have been the recommended therapeutic options for the extended...


Results from the global phase 3b ENSURE-AF ( EdoxabaN vs warfarin in subjectS UndeRgoing cardiovErsion of AtrialFibrillation ) study of...


The first non-vitamin K antagonist oral anticoagulant ( NOAC ) introduced to the market in Japan was Dabigatran ( Pradaxa...


Case reports and analyses of clinical studies and of pharmacovigilance data suggest that new oral anticoagulants ( NOACs ) are...


A study has compared efficacy and safety among novel oral anticoagulants ( NOACs ), which have not been directly compared...


The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device...


The purpose of the study was to describe the associated baseline features of atrial fibrillation patients with heart failure (...


Atrial fibrillation is often asymptomatic, but outcomes require further characterization. The study objective was to investigate the clinical presentation, management,...


Transurethral resection of the prostate ( TURP ) is considered gold standard for surgical treatment of benign prostatic hyperplasia (...


Non-vitamin K antagonist oral anticoagulants ( NOACs ) are efficacious and safe antithrombotic drugs but the non-availability of an antidote...


New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need...


Haemoptysis is a serious symptom with various aetiologies. The aim of a study was to define the aetiologies, outcomes and...


Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Clot prevention with anticoagulants might...


The new oral anticoagulants ( NOACs ) Dabigatran etexilate ( Pradaxa ), Rivaroxaban ( Xarelto ), and Apixaban ( Eliquis...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk...


The optimal antiaggregant therapy after coronary stenting in patients receiving oral anticoagulants ( OACs ) is currently debated. Search for...


The first non-vitamin K antagonist oral anticoagulant ( NOAC ) introduced to the market in Japan was Dabigatran ( Pradaxa...